ArticleEMBO molecular medicine2023
Targeting conformational changes in C-reactive protein to inhibit pro-inflammatory actions.
Article in EMBO molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Effect of single intravenous injection of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial.BMC pharmacology & toxicology · 2023Trial
- Review
- Review
- Evidence that atherosis of the spiral artery represents atherosclerotic lesions similar to those of native and transplant-induced atherosclerosis: implications for understanding the pathophysiology of obstetrical syndromes and long-term cardiovascular risk.American journal of obstetrics and gynecology · 2025Article
- Editorial: Targeting the interleukin-1β/interleukin-6/C-reactive protein pathway in clinical medicine - a road map to clinical trial design.Frontiers in cardiovascular medicine · 2025Article
- C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.Reviews in cardiovascular medicine · 2023Review
- Effects of C-reactive protein trajectories of critically ill patients with sepsis on in-hospital mortality rate.Scientific reports · 2023Review
- Targeting conformational changes in C-reactive protein to inhibit pro-inflammatory actions.EMBO molecular medicine · 2023Article
- C-reactive protein: a target for therapy to reduce inflammation.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
C-reactive protein (CRP) is a marker of acute inflammation and modulator of host defense against infections. CRP exists in conformationally distinct forms that exhibit opposing biological functions and could amplify tissue damage. Therefore, therapies that efficiently target the deleterious actions of CRP are needed. In this issue of EMBO Molecular Medicine, Zeller et al report development of a novel low molecular weight phosphocholine-mimetic that binds to pCRP and inhibits conformation change-mediated expression of pro-inflammatory actions without impairing its defense function and demonstrate its beneficial actions in preventing rejection of allograft transplants and renal ischemia-reperfusion injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.